Valentina Vurchio

Turin, 10060, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.

Journal: Cell death & disease

Published: October 07, 2025

Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer.

Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer.

Journal: Science translational medicine

Published: May 21, 2025

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

Journal: Cancer discovery

Published: April 18, 2024

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 30, 2023

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.

Journal: Science translational medicine

Published: August 16, 2023

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.

Journal: Nature communications

Published: April 26, 2023

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 16, 2022

Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways.

Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways.

Journal: Cancers

Published: May 27, 2021

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases.

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases.

Journal: Molecular systems biology

Published: May 26, 2019

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.

Journal: Science translational medicine

Published: April 26, 2019

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases.

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases.

Journal: Molecular systems biology

Published: April 14, 2019

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Journal: Oncotarget

Published: July 07, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026